Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Menopausal Estrogen-Only Therapy & Ovarian Carcinoma Risk

Obstet Gynecol; ePub 2016 Apr 4; Lee, Ness, et al

There is an increased risk of serous and endometrioid ovarian carcinoma with estrogen-only therapy use, particularly of long duration, after the age of 50 years. This according to a pooled analysis of 906 women with ovarian carcinoma and 1,220 women in a control group; all 2,126 women having reported having a hysterectomy. Researchers found:

• 43.5% of the women in the control group reported previous use of estrogen-only therapy.

• Current or recent estrogen-only therapy use was associated with an increased risk for the serous (51.4%, OR=1.63) and endometrioid (48.6%, OR=2.00) histotypes when compared to control group.

• Statistically significant trends in risk according to duration of use were seen among current or recent postmenopausal estrogen-only therapy users for both ovarian carcinoma histotypes.

• Compared with control, current or recent users for 10 years or more had increased risks of serous ovarian carcinoma (36.8%, OR=1.73) and endometrioid ovarian carcinoma (34.9%, OR=4.03).

Citation: Lee AW, Ness RB, Roman LD, et al. Association between menopausal estrogen-only therapy and ovarian carcinoma risk. [Published online ahead of print April 4, 2016]. Obstet Gynecol. doi:10.1097/AOG.0000000000001387.